EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025

Hemoglobinopathies and Red Blood Cell Disorders: A Genetic Perspective on Anemia in East Africa

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Anemia is a major public health concern in East Africa, with hemoglobinopathies and red blood cell (RBC) disorders contributing significantly to its burden. Sickle cell disease (SCD), thalassemias, and glucose-6-phosphate dehydrogenase (G6PD) deficiency are the most prevalent genetic disorders affecting hemoglobin structure and function, leading to chronic anemia and severe health complications. The high prevalence of these disorders in East Africa is driven by evolutionary selection pressures, particularly due to malaria endemicity. Despite their significant impact, hemoglobinopathies remain underdiagnosed and poorly managed due to limited healthcare infrastructure, inadequate genetic screening programs, and high treatment costs. This review explores the genetic basis, epidemiology, pathophysiology, and clinical manifestations of hemoglobinopathies in East Africa. It also examines current diagnostic and treatment strategies, highlights public health interventions, and discusses challenges in managing these disorders. Improved genetic screening, newborn screening programs, enhanced healthcare accessibility, and policy interventions are essential to mitigating the burden of hemoglobinopathies and improving health outcomes in affected populations. Addressing these challenges requires a multidisciplinary approach integrating genetic research, public health initiatives, and community-based interventions to enhance early diagnosis, treatment access, and disease prevention.

Keywords: Hemoglobinopathies, sickle cell disease, thalassemia, glucose-6-phosphate dehydrogenase deficiency.

INTRODUCTION

Anemia remains one of the most significant public health challenges in East Africa, affecting millions of individuals, particularly children and pregnant women [1]. The burden of anemia in this region is exacerbated by multiple factors, including malnutrition, infectious diseases, and genetic disorders such as hemoglobinopathies and other red blood cell (RBC) abnormalities [2]. Among these genetic conditions, sickle cell disease (SCD) and thalassemias are the most prevalent, contributing substantially to morbidity and mortality rates. Given the complex interaction between genetic predisposition, environmental factors, and public health interventions, a comprehensive understanding of hemoglobinopathies and RBC disorders is crucial for devising effective diagnostic, treatment, and preventive strategies [3]. Hemoglobinopathies are inherited disorders that affect hemoglobin structure and function, leading to various forms of anemia. The most well-known hemoglobinopathies in East Africa include sickle cell disease and beta-thalassemia. SCD, caused by a mutation in the HBB gene, results in abnormal hemoglobin (HbS) that polymerizes under low oxygen conditions, leading to sickle-shaped RBCs [4]. These distorted cells cause vaso-occlusion, chronic hemolysis, and systemic complications that significantly reduce life expectancy if left untreated. Similarly, thalassemias result from mutations that impair the production of hemoglobin chains, leading to ineffective erythropoiesis and chronic anemia [5]. The prevalence of these genetic disorders is particularly high in East Africa due to evolutionary selection pressure. The sickle cell trait (HbAS) provides partial resistance to Plasmodium falciparum malaria, which is endemic in the region [6]. This evolutionary advantage has led to the persistence of the HbS allele in populations where malaria is widespread. However, individuals inheriting two copies of the HbS allele (HbSS) suffer from sickle cell disease, which imposes a substantial health burden on affected communities. Similarly, thalassemias are prevalent in malaria-endemic regions due to similar selective pressures [7]. Despite the significant burden of hemoglobinopathies, awareness, early diagnosis, and management of these

conditions remain inadequate in many parts of East Africa. Limited healthcare infrastructure, high costs of treatment, and a lack of widespread genetic screening programs contribute to poor outcomes for affected individuals [8]. Thus, this study aims to explore the genetic basis of hemoglobinopathies and RBC disorders in East Africa, their epidemiology, and their implications for public health interventions. Hemoglobinopathies and RBC disorders are major contributors to anemia-related morbidity and mortality in East Africa. Despite their high prevalence, these conditions remain underdiagnosed and poorly managed due to several challenges [9]. First, there is limited access to genetic screening and early diagnostic tools in many rural and underserved areas. Second, many affected individuals face substantial barriers to accessing comprehensive medical care, including blood transfusions, hydroxyurea therapy, and bone marrow transplantation. Third, public health interventions in the region have historically focused more on infectious causes of anemia, such as malaria and hookworm infections, rather than genetic disorders. In addition, the socioeconomic impact of hemoglobinopathies on affected individuals and families is profound. Many children with SCD experience frequent hospitalizations, leading to school absenteeism and diminished quality of life [10]. Adults with chronic RBC disorders often face employment challenges due to recurrent health crises. The economic burden on healthcare systems is also significant, with limited resources available for specialized treatment. Addressing these issues requires a multidimensional approach that incorporates genetic research, healthcare policy improvements, and community-based interventions [11]. This study aims to investigate the genetic mutations responsible for hemoglobinopathies and RBC disorders in East Africa, assess their prevalence and distribution across different populations, investigate clinical manifestations and complications, evaluate existing diagnostic and treatment strategies, and identify gaps in healthcare services. It also explores public health interventions and policy recommendations to improve the management and prevention of hemoglobinopathies. The research questions include identifying the primary genetic mutations associated with these disorders, assessing the prevalence among different demographic groups, identifying common clinical manifestations and complications, evaluating available diagnostic and treatment strategies, and developing public health measures and policies to enhance hemoglobinopathies management and prevention. This study aims to advance knowledge and improve healthcare strategies for managing hemoglobinopathies and RBC disorders in East Africa. Understanding the genetic basis of these conditions will lead to the development of targeted diagnostic tools and personalized treatment approaches. Assessing the prevalence and clinical burden of these disorders will help policymakers allocate resources more effectively and prioritize genetic screening programs. The study will provide insights into current gaps in healthcare services, guiding efforts to improve early diagnosis, treatment accessibility, and patient support programs. It can influence national health agendas to incorporate genetic disorders into broader public health frameworks and increase awareness among healthcare professionals and communities. This research aligns with global health initiatives aimed at reducing the burden of non-communicable diseases in low- and middle-income countries. By addressing hemoglobinopathies through a genetic and public health lens, East African nations can develop sustainable strategies for improving the well-being of affected populations and achieving better health outcomes.

Genetic Basis of Hemoglobinopathies and RBC Disorders

Sickle Cell Disease (SCD): SCD is caused by a single nucleotide mutation in the beta-globin gene (HBB) on chromosome 11, leading to the production of abnormal hemoglobin S (HbS). Under low oxygen conditions, HbS polymerizes, causing RBCs to assume a sickle shape, leading to vaso-occlusion, hemolysis, and chronic anemia [12].

Thalassemias: Thalassemias result from mutations in the genes encoding alpha- or beta-globin chains, leading to defective hemoglobin production and ineffective erythropoiesis. Alpha-thalassemia is common in East Africa due to deletions in the HBA1 and HBA2 genes, while beta-thalassemia arises from mutations in the HBB gene [13].

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: G6PD deficiency, an X-linked disorder, affects RBC metabolism, making cells susceptible to oxidative stress and hemolysis. This condition contributes to hemolytic anemia and is particularly prevalent in malaria-endemic areas [14].

Epidemiology in East Africa

Hemoglobinopathies, such as sickle cell disease (SCD), thalassemias, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, are prevalent in East Africa due to genetic selection driven by malaria exposure [15]. These conditions significantly contribute to morbidity and mortality, especially in pediatric populations. SCD results from a mutation in the β-globin gene, leading to abnormal hemoglobin S (HbS). The prevalence varies by country and ethnic group but generally ranges from 1% to 5%. Thalassemias, particularly α-thalassemia, are prevalent due to their interaction with malaria resistance. α-thalassemia is widespread in Kenya and Tanzania, with gene deletions found in 40-50% of some populations [16]. β-thalassemia is rare but has been reported in Sudan and parts of Ethiopia. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked genetic disorder affecting red blood cell metabolism, leading to hemolysis upon exposure to oxidative stress. Prevalence varies widely, ranging from 10-

25% in some East African populations. More common in males due to its X-linked inheritance pattern, G6PD deficiency affects the safety of malaria treatment. The high prevalence of hemoglobinopathies in East Africa highlights the urgent need for public health interventions, including newborn screening programs, genetic counseling, malaria control strategies, and improved healthcare infrastructure to reduce the burden of these disorders.

Pathophysiology and Clinical Manifestations

Hemoglobinopathies in East Africa are a significant public health challenge, requiring multidisciplinary management approaches. The clinical presentation of these diseases varies based on genetic mutations, severity of disease, and environmental interactions, including malaria exposure, nutritional status, and access to healthcare [17]. Sickle Cell Disease (SCD) arises from a mutation in the HBB gene, leading to the production of hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes, distorting red blood cells into a sickle shape, causing vaso-occlusive crises, hemolytic anemia, stroke and neurological complications, organ damage, increased infection risk, and impaired spleen function. Thalassemias result from mutations in the HBA or HBB genes, leading to impaired hemoglobin production and microcytic anemia. Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency affects red blood cell metabolism, reducing their ability to handle oxidative stress. This deficiency is more common in males due to its X-linked inheritance pattern [14]. Early diagnosis is essential for effective management and improved outcomes. Various laboratory and genetic tests help confirm hemoglobinopathies, such as hematological tests, hemoglobin analysis, Molecular Genetic Testing, and newborn screening programs. Management strategies for hemoglobinopathies involve both supportive and curative therapies, with a focus on reducing complications and improving quality of life. SCD management includes hydrourea therapy, blood transfusions, bone marrow transplantation, infection prevention, regular blood transfusions, iron chelation therapy, gene therapy advancements, and G6PD deficiency management. Public health interventions are crucial for reducing the burden of hemoglobinopathies in East Africa. Genetic counseling and carrier screening raise awareness among high-risk populations about carrier status and family planning options, screening programs in pre-marital and antenatal clinics to inform reproductive choices. Neonatal screening initiatives implement nationwide newborn screening programs for SCD and thalassemias, enabling early diagnosis and improving survival rates [18]. Healthcare infrastructure improvement includes expanding specialized hematology clinics for long-term disease management, increasing access to affordable hydroxyurea, transfusion services, and iron chelation therapy, and training healthcare providers in early recognition and comprehensive care of hemoglobinopathies. Hemoglobinopathies remain a significant public health challenge in East Africa, necessitating multidisciplinary management approaches. Advances in genetic screening, newborn screening, and therapeutic innovations offer hope for improved outcomes, but substantial investments in healthcare infrastructure, policy implementation, and community education are needed to address the challenges faced by this population.

Challenges and Future Directions

Hemoglobinopathies, such as sickle cell disease (SCD), thalassemias, and G6PD deficiency, remain a significant burden in East Africa despite significant advances in diagnosis, treatment, and public health interventions [19]. Challenges in managing these disorders include limited access to genetic screening and early diagnosis, poor accessibility to advanced therapies, weak healthcare infrastructure, socioeconomic and cultural barriers, insufficient public awareness and preventive strategies, and inadequate policy implementation for hemoglobinopathy prevention and control. To address these challenges, future research and policy interventions should focus on advancing gene therapy and CRISPR-based interventions, expanding genetic screening and integration into healthcare services, strengthening healthcare systems and treatment accessibility, enhancing public awareness and education programs, and integrating hemoglobinopathy management into national health policies. CRISPR-Cas9 and other gene-editing technologies offer potential curative solutions by correcting genetic mutations in SCD and thalassemias. Research on affordable and scalable gene therapy models should be prioritized, and clinical trials and collaborations should be encouraged to bring advanced therapies to East Africa. Expanding genetic screening and integration into healthcare services, developing affordable hydroxyurea programs and expanding blood transfusion networks, increasing funding for hematology and sickle cell centers, and establishing public-private partnerships to subsidize bone marrow transplantation and gene therapy trials should also be prioritized [20]. Enhancing public awareness and education programs, implementing community-based awareness campaigns to reduce stigma and promote early testing, and strengthening school-based education programs on hereditary diseases and genetic health literacy are essential steps in addressing these challenges. Governments should also integrate hemoglobinopathy management into national health policies, increase funding for research, training, and patient support initiatives, and strengthen legislation on newborn screening, genetic counseling, and affordable healthcare access [21]. While hemoglobinopathies pose significant challenges in East Africa, emerging gene therapies, improved healthcare

infrastructure, and community-based interventions hold the key to better disease management. Integrating genetic screening, expanding access to treatment, and increasing public awareness will be crucial in reducing the disease burden and improving patient outcomes. Long-term government commitment, research investments, and international collaborations are essential for sustainable progress in tackling these genetic disorders.

CONCLUSION

Hemoglobinopathies and red blood cell disorders are major contributors to anemia in East Africa, exacerbating the region's public health burden. These genetic disorders, such as sickle cell disease, thalassemias, and glucose-6-phosphate dehydrogenase deficiency, pose complex challenges due to their interaction with infectious diseases, inadequate healthcare infrastructure, and socioeconomic constraints. The high prevalence of these conditions underscores the need for improved diagnostic, treatment, and prevention strategies. A comprehensive approach to managing hemoglobinopathies in East Africa requires significant investment in healthcare infrastructure, genetic screening programs, and community education. Early detection through newborn screening and genetic counseling can facilitate timely interventions, reducing disease-related morbidity and mortality. Advancements in therapeutic options, such as hydroxyurea therapy, blood transfusions, iron chelation, and emerging gene therapy techniques, offer hope for better patient outcomes. However, accessibility and affordability remain key concerns, necessitating policy reforms and international collaborations to enhance healthcare delivery. Integrating genetic insights with public health strategies can develop sustainable approaches to reducing hemoglobinopathies burden in East African nations

REFERENCES

1. Andersen, C.T., Tadesse, A.W., Bromage, S., Fekadu, H., Hemler, E.C., Passarelli, S., Spiegelman, D., Sudfeld, C.R., Worku, A., Berhane, Y., Fawzi, W.W.: Anemia Etiology in Ethiopia: Assessment of Nutritional, Infectious Disease, and Other Risk Factors in a Population-Based Cross-Sectional Survey of Women, Men, and Children. The Journal of Nutrition. 152, 501–512 (2022). https://doi.org/10.1093/jn/nxab366
2. Obeagu I E, Obeagu G. U, Igwe M C, Alum E U, Ugwu O. P C. Men's Essential roles in the Management of Sickle Cell Anemia. *Newport International Journal of Scientific and Experimental Sciences, 4, (2), 20-29* (2023)
3. Weatherall, D., Akinyanju, O., Fucharoen, S., Olivieri, N., Musgrove, P.: Inherited Disorders of Hemoglobin. In: Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., and Musgrove, P. (eds.) Disease Control Priorities in Developing Countries. The International Bank for Reconstruction and Development / The World Bank, Washington (DC) (2006)
4. Alum, E. U. Obeagu, E. I., Obeagu, G. U., Ugwu, O. P. C. Anemia as a Prognostic Marker for Disease Progression in HIV Infection. *IAA Journal of Biological Sciences.* 11(1):33-44 2023. https://doi.org/10.59298/IAAJB/2023/3.2.23310
5. Ugwu, O. P. C ., Obeagu, E. I., Obeagu, G. U., Alum, E. U.. Persistent Immune Activation and Chronic Inflammation: Unraveling Their Impact on Anemia in HIV Infection. *INOSR Experimental Sciences*, 12(3):73-84 (2023). https://doi.org/10.59298/INOSRES/2023/7.3.21322
6. Elguero, E., Délicat-Loembet, L.M., Rougeron, V., Arnathau, C., Roche, B., Becquart, P., Gonzalez, J.-P., Nkoghe, D., Sica, L., Leroy, E.M., Durand, P., Ayala, F.J., Ollomo, B., Renaud, F., Prugnolle, F.: Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci U S A. 112, 7051–7054 (2015). https://doi.org/10.1073/pnas.1505665112
7. Obeagu, E. I., Obeagu, G. U., Ugwu, O. P. C. and Alum, E. U. Navigating Hemolysis in Expectant Mothers with Sickle Cell Anemia: Best Practices and Challenges. *IAA Journal of Applied Sciences.* 2024; 11(1):30-39. https://doi.org/10.59298/IAAJAS/2024/4.78.99.11
8. Kruk, M.E., Gage, A.D., Arsenault, C., Jordan, K., Leslie, H.H., Roder-DeWan, S., Adeyi, O., Barker, P., Daelmans, B., Doubova, S.V., English, M., Elorrio, E.G., Guanais, F., Gureje, O., Hirschhorn, L.R., Jiang, L., Kelley, E., Lemango, E.T., Liljestrand, J., Malata, A., Marchant, T., Matsoso, M.P., Meara, J.G., Mohanan, M., Ndiaye, Y., Norheim, O.F., Reddy, K.S., Rowe, A.K., Salomon, J.A., Thapa, G., Twum-Danso, N.A.Y., Pate, M.: High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 6, e1196–e1252 (2018). https://doi.org/10.1016/S2214-109X(18)30386-3
9. Igwe, M. C., Obeagu, E. I., Obeagu, G. U., Alum, E. U. Ugwu, O. P. C. Men's Essential roles in the Management of Sickle Cell Anemia. Newport International Journal of Scientific and Experimental Sciences. 4(2):20-29 (2023). https://doi.org/10.59298/NIJSES/2023/10.3.1111
10. Kilonzi, M., Mwakawanga, D.L., Felician, F.F., Mlyuka, H.J., Chirande, L., Myemba, D.T., Sambayi, G., Mutagonda, R.F., Mikomangwa, W.P., Ndunguru, J., Jonathan, A., Ruggajo, P., Minja, I.K., Balandya, E.,

Makani, J., Sirili, N.: The Effects of Sickle Cell Disease on the Quality of Life: A Focus on the Untold Experiences of Parents in Tanzania. International Journal of Environmental Research and Public Health. 19, 6871 (2022). https://doi.org/10.3390/ijerph19116871

11. Egba S. I Obeagu E I, Obeagu G U, (2023) Coexisting Conditions: Addressing Diabetes in Sickle Cell Anemia Care Int. J. Curr. Res. Med. Sci. 9(11): 23-28 (2023).
12. Elendu, C., Amaechi, D.C., Alakwe-Ojimba, C.E., Elendu, T.C., Elendu, R.C., Ayabazu, C.P., Aina, T.O., Aborisade, O., Adenikinju, J.S.: Understanding Sickle cell disease: Causes, symptoms, and treatment options. Medicine (Baltimore). 102, e35237 (2023). https://doi.org/10.1097/MD.0000000000035237
13. Tamary, H., Dgany, O.: Alpha-Thalassemia. In: Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (eds.) GeneReviews®. University of Washington, Seattle, Seattle (WA) (1993)
14. Obeagu, E. I., Alum, E. U.,Obeagu, G. U. and Ugwu, O. P. C. Lifestyle, Genetics and Sickle Cell Anemia: Unveiling the Interplay of Risk Factors.International Journal of Innovative and Applied Research. 11(12):41-46 (2023). Article DOI: 10.58538/IJIAR/2060 DOI URL: http://dx.doi.org/10.58538/IJIAR/2060
15. Dixit, S., Das, A., Rana, R., Khuntia, H.K., Ota, A.B., Pati, S., Bal, M., Ranjit, M.: A community based study on haemoglobinopathies and G6PD deficiency among particularly vulnerable tribal groups in hard-to-reach malaria endemic areas of Odisha, India: implications on malaria control. Malar J. 21, 340 (2022). https://doi.org/10.1186/s12936-022-04358-5
16. Kuesap, J., Chaijaroenkul, W., Rungsihirunrat, K., Pongjantharasatien, K., Na-Bangchang, K.: Coexistence of Malaria and Thalassemia in Malaria Endemic Areas of Thailand. Korean J Parasitol. 53, 265–270 (2015). https://doi.org/10.3347/kjp.2015.53.3.265
17. Udeozor P A, Precious A U, Ibiam U A, Uti D E, Umoru G U, Onwe E N, Mbonu F. O, Omang W A, Anaga C O, Mbah J O, Ijoganu S J, Nwadum S K. Antioxidant and anti-anemic effects of ethanol leaf extracts of Mucuna poggei and Telfairia occidentalis in phenyl-hydrazine-induced anemia in Wistar albino rats. Ibnosina Journal of Medicine and Biomedical Sciences. 14(03): p. 116-126 (2022).
18. Edwards, S., Laing, N.: Genetic Counselling Needs for Reproductive Genetic Carrier Screening: A Scoping Review. J Pers Med. 12, 1699 (2022). https://doi.org/10.3390/jpm12101699
19. Thomson, A.M., McHugh, T.A., Oron, A.P., Teply, C., Lonberg, N., Vilchis Tella, et al.: Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet Haematology. 10, e585–e599 (2023). https://doi.org/10.1016/S2352-3026(23)00118-7
20. Bukini, D., Rifai, A., Kanza, C., Luoga, F., Maingu, D., Kassim, K., Mashaka, J., Kisali, E.P., Karim, S., Alimohamed, M.Z., Manongi, J., Lema, W., Chuwa, H., Konteh, S., Urio, F., Minja, I.K., Balandya, E., Moshi, G., Makani, J.: Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania. BMJ Glob Health. 18, e017878 (2025). https://doi.org/10.1136/bmjgh-2024-017878
21. Twum, S., Fosu, K., Felder, R.A., Sarpong, K.A.N.: Bridging the gaps in newborn screening programmes: Challenges and opportunities to detect haemoglobinopathies in Africa. Afr J Lab Med. 12, 2225 (2023). https://doi.org/10.4102/ajlm.v12i1.2225

CITE AS: Mugisha Emmanuel K. (2025). Hemoglobinopathies and Red Blood Cell Disorders: A Genetic Perspective on Anemia in East Africa. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):6-10